TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
TuHURA Biosciences (NASDAQ: HURA) had its price target lowered by analysts at HC Wainwright from $13.00 to $12.00. They now have a "buy" rating on the stock.
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
TuHURA Biosciences (NASDAQ: HURA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $13.00 price target on the stock.